{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High+Risk+Myeloproliferative+Neoplasms&page=10", "query": { "condition": "High Risk Myeloproliferative Neoplasms", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 233, "total_pages": 24, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High+Risk+Myeloproliferative+Neoplasms&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High+Risk+Myeloproliferative+Neoplasms&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T16:08:32.437Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01444742", "title": "Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Myeloproliferative Diseases" ], "interventions": [ { "name": "Clofarabine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 81, "start_date": "2011-11-16", "completion_date": "2017-01-29", "has_results": true, "last_update_posted_date": "2018-07-03", "last_synced_at": "2026-10-13T16:08:32.437Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01444742" }, { "nct_id": "NCT06013423", "title": "Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Leukemia of Ambiguous Lineage", "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Blastic Plasmacytoid Dendritic Cell Neoplasm", "Hematopoietic and Lymphatic System Neoplasm", "Mixed Phenotype Acute Leukemia", "Myelodysplastic Syndrome", "Myeloproliferative Neoplasm", "Non-Hodgkin Lymphoma", "Chronic Myeloid Leukemia, BCR-ABL1 Positive" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspirate", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Diagnostic Imaging", "type": "PROCEDURE" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Survey Administration", "type": "OTHER" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Umbilical Cord Blood Transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "65 Years", "sex": "ALL", "summary": "6 Months to 65 Years" }, "enrollment_count": 54, "start_date": "2024-07-23", "completion_date": "2032-10-31", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-13T16:08:32.437Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06013423" }, { "nct_id": "NCT07250646", "title": "A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Secondary AML", "Myelofibrosis" ], "interventions": [ { "name": "rebecsinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aspera Biomedicines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2026-05-21", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-10-13T16:08:32.437Z", "location_count": 3, "location_summary": "Duarte, California • Sacramento, California • San Diego, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07250646" }, { "nct_id": "NCT00002766", "title": "Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "dactinomycin", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "carmustine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "daunorubicin hydrochloride", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "mercaptopurine", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "mitoxantrone hydrochloride", "type": "DRUG" }, { "name": "pegaspargase", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 170, "start_date": "1996-03", "completion_date": "2011-09", "has_results": true, "last_update_posted_date": "2016-02-22", "last_synced_at": "2026-10-13T16:08:32.437Z", "location_count": 7, "location_summary": "Los Angeles, California • Stanford, California • Atlanta, Georgia + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "New York", "state": "New York" }, { "city": "Valhalla", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002766" }, { "nct_id": "NCT00005948", "title": "Chemotherapy Followed by Peripheral Stem Cell Transplantation And Biological Therapy in Treating Patients With Chronic Myelogenous Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "70 Years", "sex": "ALL", "summary": "Up to 70 Years" }, "enrollment_count": null, "start_date": "2000-01", "completion_date": "2001-10", "has_results": false, "last_update_posted_date": "2010-04-02", "last_synced_at": "2026-10-13T16:08:32.437Z", "location_count": 2, "location_summary": "Denver, Colorado • Seattle, Washington", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005948" }, { "nct_id": "NCT00047021", "title": "Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "mitoxantrone hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "55 Years", "sex": "ALL", "summary": "Up to 55 Years" }, "enrollment_count": 3, "start_date": "2001-11", "completion_date": "2005-09", "has_results": false, "last_update_posted_date": "2010-06-11", "last_synced_at": "2026-10-13T16:08:32.437Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00047021" }, { "nct_id": "NCT02765997", "title": "StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Lymphocytic Leukemia", "Chronic Myelogenous Leukemia", "Myelodysplasia" ], "interventions": [ { "name": "Unmanipulated UCB", "type": "BIOLOGICAL" }, { "name": "SR-1 UCB", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "2 Years to 35 Years" }, "enrollment_count": 0, "start_date": "2017-04", "completion_date": "2022-06", "has_results": false, "last_update_posted_date": "2017-12-05", "last_synced_at": "2026-10-13T16:08:32.437Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02765997" }, { "nct_id": "NCT01149915", "title": "Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myelogenous Leukemia", "Acute Lymphoblastic Leukemia", "Chronic Myelogenous Leukemia", "High-risk Myelodysplastic Syndrome", "Chronic Lymphocytic Leukemia", "Advanced Myelofibrosis" ], "interventions": [ { "name": "TH-302", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Threshold Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2010-06", "completion_date": "2013-08", "has_results": false, "last_update_posted_date": "2015-05-07", "last_synced_at": "2026-10-13T16:08:32.437Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01149915" }, { "nct_id": "NCT01465386", "title": "Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Promyelocytic Leukemia (M3)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Secondary Acute Myeloid Leukemia" ], "interventions": [ { "name": "bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2011-11", "completion_date": "2015-03-02", "has_results": true, "last_update_posted_date": "2017-04-04", "last_synced_at": "2026-10-13T16:08:32.437Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01465386" }, { "nct_id": "NCT00143559", "title": "Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Chronic Myeloid Leukemia", "Juvenile Myelomonocytic Leukemia", "Myelodysplastic Syndrome", "Paroxysmal Nocturnal Hemoglobinuria", "Hodgkin's Lymphoma", "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Systematic chemotherapy and antibodies", "type": "DRUG" }, { "name": "Allogeneic stem cell transplantation", "type": "PROCEDURE" }, { "name": "Miltenyi CliniMACS", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "DEVICE" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "2 Years to 21 Years" }, "enrollment_count": 17, "start_date": "2005-08", "completion_date": "2009-01", "has_results": false, "last_update_posted_date": "2009-01-29", "last_synced_at": "2026-10-13T16:08:32.437Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00143559" } ] }